BioAxone BioSciences Inc.
BioAxone BioSciences Inc. is a private company specialized in therapeutic drugs for unmet needs. BioAxone’s lead product, Cethrin™, is in clinical Phase II development for the treatment of acute spinal cord injury (SCI). Results from the Phase I/IIa clinical trial showed Cethrin was safe at all doses tested and cervical patients had impressive improvement in motor recovery. Cethrin has been granted Fast Track approval by the FDA, and has Orphan Drug status. The second disease targeted by BioAxone, glaucoma, affects over 70M people worldwide. The lead drug, BA-1049, is effective to reduce intraocular pressure in a monkey model of glaucoma, and is neuroprotective in preclinical studies in rats.Back to list